Wang N, Min FT, Wen WB, Cui HT. Mechanisms underlying hepatocellular carcinoma progression through N6-methyladenosine modifications of long non-coding RNA. World J Gastroenterol 2025; 31(21): 103184 [DOI: 10.3748/wjg.v31.i21.103184]
Corresponding Author of This Article
Huan-Tian Cui, PhD, The First School of Clinical Medicine, Yunnan University of Chinese Medicine, No. 1076 Yuhua Road, Chenggong District, Kunming 650000, Yunnan Province, China. 1762316411@qq.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 7, 2025; 31(21): 103184 Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.103184
Mechanisms underlying hepatocellular carcinoma progression through N6-methyladenosine modifications of long non-coding RNA
Ning Wang, Fei-Tian Min, Wei-Bo Wen, Huan-Tian Cui
Ning Wang, Fei-Tian Min, Wei-Bo Wen, Huan-Tian Cui, The First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650000, Yunnan Province, China
Co-corresponding authors: Wei-Bo Wen and Huan-Tian Cui.
Author contributions: Wang N wrote the initial manuscript draft; Min FT did the literature review; Cui HT designed the overall concept and outline of the manuscript; Wen WB did literature review and critical revision of the manuscript; Cui HT contributed to the editing of the manuscript. All authors have read and approved the final manuscript. Both Wen WB and Cui HT have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-corresponding authors of the paper.
Supported by National Natural Science Foundation of China, No. 82405223; and Yunling Scholars Program, No. XDYC-YLXZ-2022-0027.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huan-Tian Cui, PhD, The First School of Clinical Medicine, Yunnan University of Chinese Medicine, No. 1076 Yuhua Road, Chenggong District, Kunming 650000, Yunnan Province, China. 1762316411@qq.com
Received: November 19, 2024 Revised: March 26, 2025 Accepted: April 22, 2025 Published online: June 7, 2025 Processing time: 199 Days and 18.9 Hours
Core Tip
Core Tip: Yu et al present evidence showing that m6A-modified long non-coding RNA KIF9-AS1 drives the progression of hepatocellular carcinoma (HCC) and reveal novel molecular mechanisms underlying this process. The m6A modification, mediated by modification involves methyltransferase-like 3 and insulin-like growth factor insulin-like growth factor 2 mRNA-binding protein 1, stabilizes and upregulates KIF9-AS1 expression. In turn, KIF9-AS1 enhances the stability and expression of SHOX2 by promoting its deubiquitination via ubiquitin-specific peptidase 1, which strengthens stemness and contributes to sorafenib resistance in HCC cells. Future studies should further validate KIF9-AS1 as a potential diagnostic biomarker for HCC and explore its therapeutic applications in HCC treatment.
